BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

246 related articles for article (PubMed ID: 16541313)

  • 21. The "portrait" of hereditary breast cancer.
    Lacroix M; Leclercq G
    Breast Cancer Res Treat; 2005 Feb; 89(3):297-304. PubMed ID: 15754129
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Prediction of BRCA2-association in hereditary breast carcinomas using array-CGH.
    Joosse SA; Brandwijk KI; Devilee P; Wesseling J; Hogervorst FB; Verhoef S; Nederlof PM
    Breast Cancer Res Treat; 2012 Apr; 132(2):379-89. PubMed ID: 20614180
    [TBL] [Abstract][Full Text] [Related]  

  • 23. High incidence of protein-truncating TP53 mutations in BRCA1-related breast cancer.
    Holstege H; Joosse SA; van Oostrom CT; Nederlof PM; de Vries A; Jonkers J
    Cancer Res; 2009 Apr; 69(8):3625-33. PubMed ID: 19336573
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Use of expression data and the CGEMS genome-wide breast cancer association study to identify genes that may modify risk in BRCA1/2 mutation carriers.
    Walker LC; Waddell N; Ten Haaf A; ; Grimmond S; Spurdle AB
    Breast Cancer Res Treat; 2008 Nov; 112(2):229-36. PubMed ID: 18095154
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Reduction of BRCA1 protein expression in Japanese sporadic breast carcinomas and its frequent loss in BRCA1-associated cases.
    Yoshikawa K; Honda K; Inamoto T; Shinohara H; Yamauchi A; Suga K; Okuyama T; Shimada T; Kodama H; Noguchi S; Gazdar AF; Yamaoka Y; Takahashi R
    Clin Cancer Res; 1999 Jun; 5(6):1249-61. PubMed ID: 10389907
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Basal-like phenotype is not associated with patient survival in estrogen-receptor-negative breast cancers.
    Jumppanen M; Gruvberger-Saal S; Kauraniemi P; Tanner M; Bendahl PO; Lundin M; Krogh M; Kataja P; Borg A; Fernö M; Isola J
    Breast Cancer Res; 2007; 9(1):R16. PubMed ID: 17263897
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Distinct genomic aberration patterns are found in familial breast cancer associated with different immunohistochemical subtypes.
    Melchor L; Honrado E; García MJ; Alvarez S; Palacios J; Osorio A; Nathanson KL; Benítez J
    Oncogene; 2008 May; 27(22):3165-75. PubMed ID: 18071313
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Expression and prognostic significance of metalloproteases and their inhibitors in luminal A and basal-like phenotypes of breast carcinoma.
    González LO; Corte MD; Junquera S; González-Fernández R; del Casar JM; García C; Andicoechea A; Vázquez J; Pérez-Fernández R; Vizoso FJ
    Hum Pathol; 2009 Sep; 40(9):1224-33. PubMed ID: 19439346
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Abnormalities of the inactive X chromosome are a common feature of BRCA1 mutant and sporadic basal-like breast cancer.
    Ganesan S; Richardson AL; Wang ZC; Iglehart JD; Miron A; Feunteun J; Silver D; Livingston DM
    Cold Spring Harb Symp Quant Biol; 2005; 70():93-7. PubMed ID: 16869742
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Triple negative breast carcinoma and the basal phenotype: from expression profiling to clinical practice.
    Diaz LK; Cryns VL; Symmans WF; Sneige N
    Adv Anat Pathol; 2007 Nov; 14(6):419-30. PubMed ID: 18049131
    [TBL] [Abstract][Full Text] [Related]  

  • 31. p53 inactivation is a rare event in familial breast tumors negative for BRCA1 and BRCA2 mutations.
    Sensi E; Tancredi M; Aretini P; Cipollini G; Naccarato AG; Viacava P; Bevilacqua G; Caligo MA
    Breast Cancer Res Treat; 2003 Nov; 82(1):1-9. PubMed ID: 14672397
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Basal-HER2 phenotype shows poorer survival than basal-like phenotype in hormone receptor-negative invasive breast cancers.
    Liu H; Fan Q; Zhang Z; Li X; Yu H; Meng F
    Hum Pathol; 2008 Feb; 39(2):167-74. PubMed ID: 18045647
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Sporadic breast carcinomas with somatic BRCA1 gene deletions share genotype/phenotype features with familial breast carcinomas.
    Rhiem K; Todt U; Wappenschmidt B; Klein A; Wardelmann E; Schmutzler RK
    Anticancer Res; 2010 Sep; 30(9):3445-9. PubMed ID: 20944121
    [TBL] [Abstract][Full Text] [Related]  

  • 34. HMGA1 protein expression in familial breast carcinoma patients.
    Chiappetta G; Ottaiano A; Vuttariello E; Monaco M; Galdiero F; Gallipoli A; Pilotti S; Jodice G; Siranoush M; Colombo M; Ripamonti CB; Pallante PL; Radice P; Fusco A
    Eur J Cancer; 2010 Jan; 46(2):332-9. PubMed ID: 19896837
    [TBL] [Abstract][Full Text] [Related]  

  • 35. An integrative hypothesis about the origin and development of sporadic and familial breast cancer subtypes.
    Melchor L; Benítez J
    Carcinogenesis; 2008 Aug; 29(8):1475-82. PubMed ID: 18596026
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Mutation analysis of BRCA1 and BRCA2 from 793 Korean patients with sporadic breast cancer.
    Han SH; Lee KR; Lee DG; Kim BY; Lee KE; Chung WS
    Clin Genet; 2006 Dec; 70(6):496-501. PubMed ID: 17100994
    [TBL] [Abstract][Full Text] [Related]  

  • 37. High frequency of HIF-1alpha overexpression in BRCA1 related breast cancer.
    van der Groep P; Bouter A; Menko FH; van der Wall E; van Diest PJ
    Breast Cancer Res Treat; 2008 Oct; 111(3):475-80. PubMed ID: 18030615
    [TBL] [Abstract][Full Text] [Related]  

  • 38. BRCA1 in non-inherited breast carcinomas (Review).
    Yang Q; Yoshimura G; Nakamura M; Nakamura Y; Suzuma T; Umemura T; Mori I; Sakurai T; Kakudo K
    Oncol Rep; 2002; 9(6):1329-33. PubMed ID: 12375043
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The prevalence of BRCA1 and BRCA2 germline mutations in high-risk breast cancer patients of Chinese Han nationality: two recurrent mutations were identified.
    Li WF; Hu Z; Rao NY; Song CG; Zhang B; Cao MZ; Su FX; Wang YS; He PQ; Di GH; Shen KW; Wu J; Lu JS; Luo JM; Liu XY; Zhou J; Wang L; Zhao L; Liu YB; Yuan WT; Yang L; Shen ZZ; Huang W; Shao ZM
    Breast Cancer Res Treat; 2008 Jul; 110(1):99-109. PubMed ID: 17851763
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Deletions on chromosome 4 in sporadic and BRCA mutated tumors and association with pathological variables.
    Johannsdottir HK; Johannesdottir G; Agnarsson BA; Eerola H; Arason A; Johannsson OT; Heikkilä P; Egilsson V; Olsson H; Borg A; Nevanlinna H; Barkardottir RB
    Anticancer Res; 2004; 24(5A):2681-7. PubMed ID: 15521105
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.